AMGN Stock Recent News

DeLLphi-303 Study Results Show Potential for IMDELLTRA in Combination with a PD-L1 Inhibitor as First-Line Maintenance Therapy in ES-SCLC DeLLphi-301 Long-Term Follow-up Data Demonstrate Sustained Safety and Efficacy for IMDELLTRA THOUSAND OAKS, Calif. , Sept. 9, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new data showcasing IMDELLTRATM (tarlatamab-dlle), a first-in-class delta-like ligand 3 (DLL3)-targeting Bispecific T-cell Engager (BiTE®) molecule, at the 2024 World Conference on Lung Cancer (WCLC) in San Diego.

Amgen Inc. (NASDAQ:AMGN ) Morgan Stanley 22nd Annual Global Healthcare Conference September 4, 2024 9:15 AM ET Company Participants Bob Bradway - Chairman and Chief Executive Officer Conference Call Participants Terence Flynn - Morgan Stanley Operator Terence Flynn Great. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures.

Amgen will test its obesity drug candidate in patients at risk of obesity-related conditions such as heart, liver and kidney diseases in its late-stage trial, the company's CEO Robert Bradway said at a Morgan Stanley healthcare conference on Wednesday.

From obesity to cancer, investors will do well to watch these 6 clinical trials.

THOUSAND OAKS, Calif. , Aug. 29, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Morgan Stanley 22nd Annual Global Healthcare Conference at 9:15 a.m.

The weight-loss drugs market could be worth up to $144 billion within six years. And a bevy of pharma stocks could get a lift.

The Investment Committee give you their top stocks to watch for the second half.

On August 6, Amgen released financial results for the second quarter of 2024, which pleasantly shocked me thanks to strong sales of its oncology and rheumatology franchises. So, Evenity sales reached $391 million for the three months ended June 30, 2024, increasing by 39.1% year-on-year. While sales of an equally important medication, namely Krystexxa, amounted to $294 million in the second quarter of 2024, an increase of 25.1% quarter-on-quarter.

While Eli Lilly & Co. and Novo Nordisk dominate the obesity-drug market, there's a vast field of would-be competitors closing in behind them — and the most successful among those next-wave contenders stand to capture up to 20% of the lucrative market, Jefferies analysts said in a research note Monday.

First and Only Pill for Children and Adolescents Ages 6-17 with Moderate to Severe Plaque Psoriasis THOUSAND OAKS, Calif. , Aug. 20, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced Otezla® (apremilast) is now available in the U.S. for pediatric use.